Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Sarcoma 1573Glioblastoma 512Gliosarcoma 485Osteosarcoma 459Brain Neoplasms 344Gastrointestinal Stromal Tumors 326Central Nervous System Neoplasms 296Neoplasms 291Dendritic Cell Sarcoma, Interdigitating 286Astrocytoma 275Lymphoma 260Bone Neoplasms 245Sarcoma, Ewing 238Breast Neoplasms 238Glioma 237Neuroblastoma 230Rhabdomyosarcoma 227Melanoma 225Precursor Cell Lymphoblastic Leukemia-Lymphoma 218Recurrence 216Lymphoma, Non-Hodgkin 216Burkitt Lymphoma 213Oligodendroglioma 203Ovarian Neoplasms 202Lymphoma, Large B-Cell, Diffuse 187Neoplasm Metastasis 186Lymphoma, Follicular 172Leukemia 164Leukemia, Lymphocytic, Chronic, B-Cell 158Hodgkin Disease 158

Interventions

ganitumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Insulin-Like Growth Factor I, Resistance To × Sarcoma × Clear all
NCT00563680 2016-10-27

QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors

NantCell, Inc.

Phase 2 Completed
38 enrolled
Sarcoma

Askin Tumor, Insulin-Like Growth Factor I, Resistance To, Sarcoma, Sarcoma, Ewing, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡